http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
갱년기 골다공증 환자의 HRT와 Alendronate 1년 병합치료 효과
오한진(Han Jin Oh),임창훈(Chang Hun Lim),정호연(Ho Yeon Chung),한기옥(Ki Ok Han),장학철(Hak Chul Jang),윤현규(Hyun Koo Yoon),한인권(In Kwon Han) 대한폐경학회 2000 대한폐경학회지 Vol.6 No.1
N/A Background; Rate of bone loss should be increased after menopause and then formation coupled with resoprtion also be increased. Alendronate (Fosamax ;MSD, Rahway, NJ, USA), an antiresorptive drug known to be helpful to prevent bone loss. Alendronate is one of antiresorptive drug for treatment of osteoporosis and resulted in a decrease of bone turnover, There are no available data about Korean people, So, we wanted to determine the effects of alendronate in Korean postmenopausal osteoporosis patients after 1- year treatment Subjects and Methods; We studied 42 women with postmenopausal osteoporosis (bone mineral density[BMD] T score<2.5) who visited osteoporosis clinic in Samsung Cheil Hospital from Jan. 1999 to Apr. 2000, Subjects were stratified in 2 groups. Group 1 treated with alendronate 10mg/day and estrogen, and Group 2 treated with estrogen alone. BMD at the lumbar spine were measured at baseline and 1-year after treatment. We also measured serum marker of bone formation (total alkaline phosphatase[Alk]), and marker of bone resorption (deoxypyridinoline [DPYD]) from urine at baseline, 3months and I-year after treatment. Results; The mean differences in changes of markers after 3 months and 1 year of treatment were remarked significantly (3-Month; delta Alk:-28,7±3.6%, delta DPYD:-31.0±5,4% vs 1-Year; delta Alk:-32.2±3.1%, delta DPYD:-23.0±3.5%). Markers of bone metabolism showed no significant responses between two groups at 3 months and 1year after treatment, Also, Bone mineral density at lumbar spine was significantly increased in Group treated with alendronatc and estrogen than estrogen only group (9.6±0,7% vs 5.3±0.6%, P<0,001). Conclusion; Our data showed that using alendronate with estrogen to the patients of Korean women with osteoporosis increase bone mineral density more, So, we concluded that alendronate therapy with estrogen was helpful to manage postmenopausal osteoporosis patients.
폐경 여성의 골밀도 변화를 중심으로 한 치료 방법의 비용효과적 비교
오한진 ( Han Jin Oh ),김의현 ( Ui Hyun Kim ),오장균 ( Jang Kyun Oh ),윤현구 ( Hyun Koo Yoon ),한인권 ( In Kwon Han ) 대한폐경학회 2001 대한폐경학회지 Vol.7 No.1
N/A Background : There were many strategies to treat postmenopausal women with osteoporosis. Because of bone mass measurement confirms the existence of osteoporosis and also predicts the risk of fracture, the effectiveness of the treatment should be measured by the amount of increased bone mass. Methods : 311 postmenopausal Korean women were evaluated who visited one of university hospital located in Seoul from Aug. 1997 to July 2000, with respect to markers of bone turnover and BMD at lumbar spine. Subjects were classified into 3 groups, peri-menopause, early-menopause, and late-menopause by menopausal states. To evaluate the cost-effectiveness of treatment, we compared changes of BMD after 1-year of treatment and total drug costs for 1-year among 3 groups. And also to evaluated the cost-effectiveness between groups classified by WHO criteria, we also compared changes of BMD and total drug costs after 1-year. Results : Our results showed those findings: 1. The const-effectiveness was similar among 3 groups classified by the menopausal state. 2. Among three groups classified by bone density, osteopenia group showed significantly favorable cost-effectiveness score than normal or osteoporotic group.
한국 폐경 여성에서 이중에너지 방사선 흡수 계측기 ( DEXA ) 의 요추 및 대퇴골 골밀도 표준화
최규홍(Kyu Hong Choi),한인권(In Kwon Han) 대한폐경학회 2000 대한폐경학회지 Vol.6 No.1
N/A Objectives: Bone densitometry is a current method for evaluating skeletal status, assessing osteoporosis, and determining fracture risk. DEXA has rapidly became a dominant method for evaluating skeletal status, But the comparison of patient data among different DHXA scanners is complicated because the instruments show differences in scanner design, bone mineral calibration, and analysis algorithms, and scan site. This study was performed to establish appropriate cross-calibration parameters at the lumbar and femoral sites among two models of DEXA system from different manufacturers. Materials and Methods: In our study, 63 healthy, Korean women aged 37-81 years(mean age:57.1+7,03) were examined, Posteroanterior Lumbar spine (L2-L4) and hip measurements were obtained on a Hologic QDR 4500, and a Noland XR-36 densitometer. All subjects had no spinal deformities, osteophytes, fractures and scoliosis, bilateral hip replacements, and other conditions that could affect BMD measurements. We performed the measurement of BMD in each subject with different two scanners at two scan sites at the same time, Results: The correlations of the patients' spinal BMD(r 0.971) and femoral neck BMD(r 0.905) were excellent for each of the two scanner pairs. From the linear regression analysis of the patient data, cross calibration equations for spinal and femoral neck BMD values were derived, The BMD values at the lumbar spine and proximal femur measured using different scanner showed different proportion of diagnostic criteria in osteoporosis. Conclusion: Even though it has some limitations, the standardization approach as performed in our study may provide compatibility of DEXA results obtained on different scanners
정상 임신후반기 IGF - I / SMC 와 신생아 성장에 관한 연구
최웅환(Woong Hwan Choi),박원근(Won Kun Park),신현호(Hyun Ho Shin),한인권(In Kwon Han),김선우(Sun Woo Kim),최영길(Young Kil Choi) 대한내과학회 1988 대한내과학회지 Vol.34 No.2
N/A The polypeptide hormones of the somatemedin (SM) family have been proposed to promote growth both in pre and postnatally. The two main farm of samatomedin in serum of adults are insulin-like growth factor 1, also termed SMC and IGF-II. IGF-I activity raises in the late pegnancy, which suggest a potential effect on fetal development. The aim of the present study was to determine maternal IGF-I and placenta IGF-I levels in 12 womens with late pregnancy end evaluate the relationship of these level to the growth percentile of their infant. The result were as follow: 1) plasma levels of IGF-I/SMC in late pregnancy were signficantly higher than age mached control. (337±127ng/ml VS 232±15ng/ml, p<0.005). 2) The maternal levels of IGF-I/SMC (337±127ng/ml) were significantly greater than those in the paired newborn cord artery (84±40ng/ml) or cord vein (100±46ng/ml). 3) The maternal levels of IGF-I/SMC were not correlated with cord vein IGF-I/SMC r=18 and cord artery IGF-I/SMC r=0.16 (p>0.05). 4) The cord vein IGF-I/SMC levels were positively correlated with cord artery IGF-I/SMC levels r=0.76 (p<0.005). 5) There was an increase in the percentile of birth weight and length with increasing maternal serum 1GF-1/SMC levels. The corresponding correlation coefficients in weight and length percentile with maternal serum IGF-l/SMC were 0.44 (p<0.005) and 0.65 (p<0.005), respectively. These result suggest that increased IGF-I/SMC levels in late pregnancy may causally be related to intrauterine fetal growth.
Type 2 DM 환자에서 적혈구를 이용한 인슐린 내재화율과 Degradation Products 에 관한 연구
최웅환(Woong Hwan Choi),박원근(Won Kun Park),한인권(In Kwon Han),김선우(Sun Woo Kim),정운원(Woon Won Jung),문인걸(In Gul Moon) 대한내과학회 1988 대한내과학회지 Vol.34 No.3
N/A We studied insulin internalization and degradation at 37℃ in human erythrocytes from patients with type II DM and normal subjects. The internalization of 125I-Insulin in human erythrocytes was studied by using an acid extraction technique (pH 5.7, PBS) from 54 patients with type II DM and 14 normal subjects. Insulin degradation products was assayed with using Sephadex G-50 column, HPLC with radioisotope detector from 4 patients with type II DM and 14 normal subjects. The maximal rate of insulin internalization (Incubation time: 4hours, at 37℃) was decreased in patients with type II DM [51.40±14.67% (±SD) VS 80.23±7.73 % (±SD). P<0.001]. The maximal degradation products of insulin (Incubation time: 4hours, at 37℃) was decreased in patients with type II DM [62.50±10.50% (±SD) VS 87.75±6.66% (SD). p<0.001]. In conclusion, insulin internalization and degradation in human eryhrocytes from patients with type II DM are significantly reduced. These defect may be related to the cellular insulin resistance present in these patients.